SCHEMBL2643619

SCHEMBL2643619

N#CCCC1c2c(Cl)cccc2C(=O)N1Cc1ccc(F)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
LMNA P02545 3/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
HPGD P15428 2/20 0.42
KDM4E B2RXH2 2/20 0.42
MEN1 O00255 2/20 0.42
HTT P42858 2/20 0.42
KMT2A Q03164 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MAPT P10636 2/20 0.40
CYP1A2 P05177 2/20 0.38
CYP2C19 P33261 2/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CASP3 P42574 1/20 0.37
UBE2N P61088 1/20 0.37
ATM Q13315 1/20 0.37
P2RX7 Q99572 1/20 0.36
IDO1 P14902 1/20 0.36
TDO2 P48775 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2645436 0.82 KDM4E (0.45) ALDH1A1LMNAL3MBTL1HPGDKDM4E
SCHEMBL2644952 0.82 MAPT (0.36) LMNAL3MBTL1HPGDHTTKMT2A
SCHEMBL2643454 0.81 ALDH1A1 (0.34) ALDH1A1LMNAL3MBTL1HPGDKDM4E
SCHEMBL2645257 0.78 ALDH1A1 (0.39) ALDH1A1LMNAL3MBTL1HPGDKDM4E
SCHEMBL2643920 0.78 HCRTR1 (0.36) ALDH1A1LMNAL3MBTL1HPGDKDM4E
SCHEMBL2644120 0.78 RORC (0.36) ALDH1A1KDM4EMAPTATM
SCHEMBL2643529 0.78 CYP2C19 (0.42) ALDH1A1MEN1KMT2ACYP1A2CYP2C19
SCHEMBL2644231 0.74 KDM4E (0.46) ALDH1A1LMNAL3MBTL1HPGDKDM4E
SCHEMBL2643582 0.74 MAPT (0.40) ALDH1A1LMNAL3MBTL1HPGDKDM4E
SCHEMBL2664915 0.72 CASP3 (0.39) ALDH1A1LMNAL3MBTL1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8796313-B2 Substituted dihydroisoindolones as allosteric modulators of glucokinase JANSSEN PHARMACEUTICA N.V. (BE) 2014-08-05 US disclosed
CN-101316836-A Substituted dihydroisoindolones as allosteric modulators of glucokinase JANSSEN PHARMACEUTICA NV (BE) 2008-12-03 CN disclosed
EP-1960385-A1 SUBSTITUTED DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-08-27 EP disclosed
WO-2007053503-A1 SUBSTITUTED DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-10 WO disclosed
US-20070099930-A1 Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099930-A1 Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase GCK, GCKR, GPR119 ALDH1A1 1552/4885LMNA 4676/4885L3MBTL1 4696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.